RxDoctor Payments Data

Aisha Maldonado

Adult Health · Orlando, FLNPI 1578035903

Payments from drug & device makers

$4,669in general payments, 2019–2025

Across 142 payments — averaging $32.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$871
  • Shockwave Medical, Inc$684
  • E.r. Squibb & Sons, L.L.C.$370
  • Boehringer Ingelheim$341
  • Boston Scientific$303
  • Johnson & Johnson$261
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$4,58698%
  • Education$301%
  • Gifts$541%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,669 in reported general payments places this provider in the 90th percentile of 2,237 adult health providers in Florida.

See all adult health providers in Florida

Medicare billing

Part B allowed, 2024
$5,043
Medicare patients
38
Services billed
76

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis15$552,846
EntrestoSacubitril/Valsartan112$149,315
JardianceEmpagliflozin89$101,833
EliquisApixaban100$94,306
FarxigaDapagliflozin Propanediol43$53,950
Torsemide161$3,559
Ranolazine ErRanolazine13$2,535
Metoprolol Succinate92$1,593
Bumetanide29$1,331
Hydralazine Hcl33$1,085
Carvedilol57$583
Potassium Chloride33$534
Spironolactone70$524
Furosemide78$477
Isosorbide Mononitrate ErIsosorbide Mononitrate25$388

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$137$647,151115 claims
NovartisEntresto$220$149,315112 claims
Boehringer IngelheimJardiance$341$101,83389 claims
AstraZenecaFarxiga$871$53,95043 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,237 adult health providers in Florida.

Other adult health in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →